Affordable Access

Publisher Website

Prior Evidence of Putative Novel Rhinovirus Species, Australia

Centers for Disease Control and Prevention
Publication Date
DOI: 10.3201/eid1411.080725
  • Letters To The Editor
  • Biology
  • Medicine


Letters.indd LETTERS plant, and pulmonary infection with M. kansasii developed in 2 recipients of lung transplants (5). There is also a case report of systemic M. bovis in- fection developing in a patient with relapsing B chronic lymphocytic leu- kemia after administration of alemtu- zumab (10). Although we believe that alem- tuzumab is responsible for the severe immunosuppression that predisposed these patients to M. haemophilum in- fection, other explanations are plau- sible. For example, patient 1 had re- ceived rituximab and cyclophosamide for 6 months. These drugs, in addition to his underlying disease of chromic lymphocytic leukemia, may have pre- disposed him to M. haemophilum in- fection. However, his lesions did not appear until he received alemtuzumab. In patient 2, the immunosuppression associated with his transplant may have predisposed the patient to M. haemophilum infection. This report identifi es M. haemo- philum as an opportunistic pathogen in patients who have received alem- tuzumab. We recommend that all patients who have received at least 1 dose of alemtuzumab, and who have undiagnosed tender skin lesions lo- cated over the extremities, be evalu- ated by using appropriate techniques to isolate M. haemophilum. Commu- nication with microbiology laborato- ry staff concerning appropriate meth- ods for detection of the organism is crucial. Mini Kamboj, Eddie Louie, Timothy Keihn, Genovefa Papanicolaou, Michael Glickman, and Kent Sepkowitz Author affi liations: Memorial Sloan-Ketter- ing Cancer Center, New York, New York, USA (M. Kamboj, T. Keihn, G. Papanico- laou, M. Glickman, K. Sepkowitz); and New York University, New York (E. Louie) DOI: 10.3201/eid1411.071321 References 1. Ferrajoli A, O’Brien S, Keating MJ. Alem- tuzumab: a novel monoclonal antibody. Expert Opin Biol Ther. 2001;1:1059–65. DOI: 10.1517/14712598.1.6.1059 2. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzum

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times